Comparing Nuvilex (NASDAQ:PMCB) & Avadel Pharmaceuticals (NASDAQ:AVDL)

Avadel Pharmaceuticals (NASDAQ:AVDL) and Nuvilex (NASDAQ:PMCB) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Risk & Volatility

Avadel Pharmaceuticals has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Nuvilex has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Avadel Pharmaceuticals and Nuvilex, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avadel Pharmaceuticals	2	10	1	0	1.92
Nuvilex	1	0	0	0	1.00

Avadel Pharmaceuticals presently has a consensus target price of $18.13, suggesting a potential downside of 15.11%. Given Avadel Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Avadel Pharmaceuticals is more favorable than Nuvilex.

Earnings and Valuation

This table compares Avadel Pharmaceuticals and Nuvilex”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avadel Pharmaceuticals	$169.12 million	12.33	-$48.83 million	N/A	N/A
Nuvilex	N/A	N/A	$30.66 million	($0.54)	-2.24

Nuvilex has lower revenue, but higher earnings than Avadel Pharmaceuticals.

Institutional and Insider Ownership

69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.2% of Nuvilex shares are owned by institutional investors. 5.2% of Avadel Pharmaceuticals shares are owned by insiders. Comparatively, 10.3% of Nuvilex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Avadel Pharmaceuticals and Nuvilex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avadel Pharmaceuticals	-0.11%	-0.33%	-0.15%
Nuvilex	N/A	-6.41%	-5.77%

Summary

Avadel Pharmaceuticals beats Nuvilex on 8 of the 11 factors compared between the two stocks.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

About Nuvilex

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.